Evidence map›Paper›PMID 27811356›Full record

ArticleOncotarget2016

Spatio-temporal regulation of EGFR signaling by the Eps15 homology domain-containing protein 3 (EHD3).

Mohamed Amessou, Abdul Shukkur Ebrahim, Ashok Dilly, Melvin Joseph, Marina Tabolina, Sahiti Chukkapalli, Louay Meroueh, Joseph T Syed, Allison Liddane, Siera Lanae Lang and 2 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Mohamed AmessouDepartment of Pathology, Wayne State University School of Medicine, Detroit, Michigan, USA.
Abdul Shukkur EbrahimLymphoma Research Lab, Wayne State University School of Medicine, Detroit, Michigan, USA.
Ashok DillyDepartment of Pathology, Wayne State University School of Medicine, Detroit, Michigan, USA.
Melvin JosephDepartment of Pathology, Wayne State University School of Medicine, Detroit, Michigan, USA.
Marina TabolinaDepartment of Pathology, Wayne State University School of Medicine, Detroit, Michigan, USA.
Sahiti ChukkapalliDepartment of Pathology, Wayne State University School of Medicine, Detroit, Michigan, USA.
Louay MerouehDepartment of Pathology, Wayne State University School of Medicine, Detroit, Michigan, USA.
Joseph T SyedDepartment of Pathology, Wayne State University School of Medicine, Detroit, Michigan, USA.
Allison LiddaneLymphoma Research Lab, Wayne State University School of Medicine, Detroit, Michigan, USA.
Siera Lanae LangDepartment of Pathology, Wayne State University School of Medicine, Detroit, Michigan, USA.
Ayad Al-KatibLymphoma Research Lab, Wayne State University School of Medicine, Detroit, Michigan, USA.
Mustapha KandouzDepartment of Pathology, Wayne State University School of Medicine, Detroit, Michigan, USA.
Wayne State University · USThe Barbara Ann Karmanos Cancer Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The epidermal growth factor (EGF) receptor EGFR is a major receptor tyrosine kinase whose role in gliomagenesis is well established. We have recently identified EHD3 [Eps15 homology (EH) domain-containing protein 3], an endocytic trafficking regulatory protein, as a putative brain tumor suppressor. Here, we investigate the underlying mechanisms, by establishing a novel mechanistic and functional connection between EHD3 and the EGFR signaling pathway. We show that, in response to stimulation with the EGF ligand, EHD3 accelerates the rate of EGFR degradation by dramatically increasing its ubiquitination. As part of this process, EHD3 also regulates EGFR endosomal trafficking by diverting it away from the recycling route into the degradative pathway. Moreover, we found that upon EGF activation, rather than affecting the total MAPK and AKT downstream signaling, EHD3 decreases endosome-based signaling of these two pathways, thus suggesting the contribution of EHD3 in the spatial regulation of EGFR signaling. This function explains the higher sensitivity of EHD3-expressing cells to the growth-inhibitory effects of EGF. In summary, this is the first report supporting a mechanism of EHD3-mediated tumor suppression that involves the attenuation of endosomal signaling of the EGFR oncogene.

Indexed as

Brain NeoplasmsCarrier ProteinsCell Line, TumorEndosomesEpidermal Growth FactorErbB ReceptorsExtracellular Signal-Regulated MAP KinasesGliomaHumansMutationProtein TransportProteolysisProto-Oncogene Proteins c-aktSignal TransductionUbiquitinationCarrier ProteinsEGFR protein, humanEHD3 protein, humanEpidermal Growth FactorErbB ReceptorsExtracellular Signal-Regulated MAP KinasesProto-Oncogene Proteins c-aktEGFREHD3glioblastomasignaling

Identifiers

PMID27811356
PMCPMC5346708
OpenAlexW2548123013

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.